Aronora, Inc.
Publicly observedPortland, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Portland | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Aronora, Inc. | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | K57JWU3XKX95 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant15 Jun 2024Publicly observed
NIH SBIR/STTR award: Contact Pathway Inhibitor to Prevent Catheter-Related Thrombosis
USD 1,069,527.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
- Grant15 Jun 2024Publicly observed
NIH SBIR/STTR award: Contact Pathway Inhibitor to Prevent Catheter-Related Thrombosis
USD 1,069,527.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
- Grant1 Jun 2023Publicly observed
NIH SBIR/STTR award: Contact Pathway Inhibitor to Prevent Vascular Access Failure
USD 1,331,056.00 · National Heart Lung and Blood Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.